期刊文献+

中空纤维感染模型概述及其应用于抗菌及抗病毒药物开发的研究现状 被引量:1

Current situation of hollow fiber infection model and its application in the research of antibacterial and antiviral agents
原文传递
导出
摘要 中空纤维感染模型(hollow fiber infection model,HFIM)是一种新药开发和应用的重要工具,被广泛应用于抗菌及抗病毒药物的试验中。该模型可用于研究体外抗菌活性(pharmacodynamics, PD)与抗菌药物的药代动力学行为(pharmacokinetics, PK)之间的关系,模拟体内给药后的连续变化,呈现患者体内的抗菌药物浓度-时间曲线。应用HFIM得到的实验结果与细菌杀灭的临床终点和出现耐药性的时间进程密切相,能够为后续药物临床试验的设计提供支持。 Hollow fiber infection model(HFIM) is an important tool for the development and utilization of new drugs,which is widely used in the trials of antibacterials and antivirals. This model can be used to study the relationship between the in vitro antibacterial activity(pharmacodynamics, PD) and the pharmacokinetics(PK) of antibacterial agents. Furthermore, it can also be used to simulate the continuous changes of agents in vivo after administration and describe the concentration-time curve of antibacterials observed in patients. The experimental results obtained by HFIM are closely related to the clinical endpoint of bacterium killing and the time course of drug resistance, which can provide support for the design of follow-up drug clinical trials.
作者 冀希炜 李耘 吕媛 JI Xi-wei;LI Yun;LüYuan(Institute of Clinical Pharmacology,Peking University First Hospital,Beijing 100034,China)
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2020年第16期2513-2516,共4页 The Chinese Journal of Clinical Pharmacology
基金 国家自然科学基金资助项目(81803614)。
关键词 中空纤维感染模型 抗菌药物 细菌耐药 模拟 hollow fiber infection model antibacterial drug bacterial resistance simulation
  • 相关文献

参考文献5

二级参考文献12

  • 1史军.药物动力学和药效动力学在抗菌药物新药开发和临床治疗上的应用[J].中国临床药理学与治疗学,2007,12(2):121-133. 被引量:34
  • 2Turnidge J, Paterson DL. Setting and revising antibacterial suscepti- bility breakpoints [ J ]. Clin Microbiol Rev, 2007,20:391 - 408.
  • 3Turnidge J, Kahlmeter G, Kronvall G. Statistical characterization of bacterial wild - type MIC value distributions and the determination of epidemiologieal cut - off value [J]. Clin Microbiol Infect, 2006,12 : 418 -425.
  • 4Asin - prieo E, Rodriguez - Gascon A, Isla A. Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicro- bial agents[ J]. J Infect Chemother, 2015, 21319 - 329.
  • 5Owens RC Jr, Shorr AF. Rational dosing of antimicrobial agents: phar- macokinetic and pharmacodynamics strategies [ J ]. Am J Health Syst Pharm, 2009,66(Suppl. 4) :S23 - S30.
  • 6Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics - pharmacodynamics of antimicrobial therapy : it's not just for mice any- more [ J]. Clin lnfec Dis, 2007,44:79 - 86.
  • 7Amsterdam D. Antibiotics in Laboratory Medicine [ M]. 6th edition. Philadelphia: Wohers Kluwer, 2015:9 - 16.
  • 8Andes D, Craig WA. Animal model pharmacokinetics and pharmaco- dynamics: a critical review [J]. lnt J Antimicrob Agents, 2002, 19: 261 - 268.
  • 9Clinical and Laboratory Standards Institute. 2008 Development of in vitro susceptibility testing criteria and quality control parameters: ap- proved guideline - 3 rd ed. [ M]. CLSI document M23 - A3 CLSI,Wayne, PA.
  • 10郎美琦,蒋利,黄佳盛.抗结核病药物治疗综述[J].临床肺科杂志,2010,15(8):1153-1154. 被引量:12

共引文献336

同被引文献3

  • 1<抗菌药物临床试验技术指导原则>写作组.抗菌药物临床试验技术指导原则[J].中国临床药理学杂志,2014,30(9):844-856. 被引量:322
  • 2黄晓岚,卞星晨,黄志伟,毋海兰,张菁.新型β内酰胺类-β内酰胺酶抑制剂复方制剂研究进展[J].中国感染与化疗杂志,2021,21(2):241-248. 被引量:6
  • 3胡付品,郭燕,朱德妹,汪复,蒋晓飞,徐英春,张小江,张朝霞,季萍,谢轶,康梅,王传清,王爱敏,徐元宏,黄颖,孙自镛,陈中举,倪语星,孙景勇,褚云卓,田素飞,胡志东,李金,俞云松,林洁,单斌,杜艳,郭素芳,魏莲花,邹凤梅,张泓,王春,胡云建,艾效曼,卓超,苏丹虹,郭大文,赵金英,喻华,黄湘宁,刘文恩,李艳明,金炎,邵春红,徐雪松,鄢超,王山梅,楚亚菲,张利侠,马娟,周树平,周艳,朱镭,孟晋华,董芳,郑红艳,胡芳芳,沈瀚,周万青,贾伟,李刚,吴劲松,卢月梅,李继红,段金菊,康建邦,马晓波,郑燕萍,郭如意,朱焱,陈运生,孟青,王世富,胡雪飞,沈继录,汪瑞忠,房华,俞碧霞,赵勇,龚萍,温开镇,张贻荣,刘江山,廖龙凤,顾洪芹,姜琳,贺雯,薛顺虹,冯佼,窦睿,岳春雷.2020年CHINET中国细菌耐药监测[J].中国感染与化疗杂志,2021,21(4):377-387. 被引量:335

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部